Inhibition of spontaneous platelet aggregation by sulfinpyrazone.
In a randomized double-blind crossover study in 16 patients with enhanced in vitro spontaneous platelet aggregation, sulfinpyrazone proved to be effective in normalizing platelet aggregability within 4 days after initiation of therapy.
D000368:Aged; D001161:Arteriosclerosis / Q000097:blood; D003920:Diabetes Mellitus / Q000097:blood; D004311:Double-Blind Method; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D012907:Smoking / Q000150:complications; D013442:Sulfinpyrazone / Q000627:therapeutic use*; D013923:Thromboembolism / Q000097:blood; D013997:Time Factors
D013442:Sulfinpyrazone